

EVKEEZA is a 60-minute IV infusion every 4 weeks¹



	Dosage within		Dosage within
i <23 kg	≤1 vial	₩ 92.1-115 kg	4-5 vials
ii 23.1−46 kg	1-2 vials	115.1–138 kg	5-6 vials
iii 46.1-69 kg	2-3 vials	138.1+ kg	6+ vials
69.1-92 kg	3-4 vials	Vial size is 345 mg/2.3 mL	

The dosage for EVKEEZA should be calculated using the patient's weight at 15 mg/kg¹

The recommended dose is 15 mg/kg administered by intravenous infusion over 60 minutes every 4 weeks. The rate of infusion may be slowed, interrupted or discontinued if the patient develops any signs of adverse reactions, including infusion-associated symptoms.

Missed dose

If a dose is missed, it should be administered as soon as possible. Thereafter, treatment with EVKEEZA should be scheduled every 4 weeks from the date of the last dose.

Overdose

There is no specific treatment for EVKEEZA overdose. In the event of an overdose, the patient should be treated symptomatically, and supportive measures should be instituted as required. For management of a suspected drug overdose, contact your regional poison control centre.

Indication:


EVKEEZA (evinacumab for injection) is indicated as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients 6 months of age and older with homozygous familial hypercholesterolemia (HoFH).

The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined.

EVKEEZA can be administered without regard to lipoprotein apheresis¹

Women of childbearing potential should use effective contraception during treatment with EVKEEZA and for at least 5 months after the last dose of EVKEEZA.

Example calculation for the amount of EVKEEZA (mL) recommended if patient weighs 100 kg:







Preparation¹

- 1. Calculate dose and number of vials required. EVKEEZA is preservative-free and is supplied as a single use only. During preparation and reconstitution, a strictly aseptic technique must be used.
- 2. Visually inspect the medicinal product for cloudiness, discolouration or particulate matter prior to administration. EVKEEZA is a clear to slightly opalescent, colourless to pale yellow solution. Discard the vial if the solution is cloudy, discoloured or contains particulate matter. Do not shake the vial.
- 3. Withdraw the required volume of EVKEEZA from the vial(s) based on patient's weight, and transfer into an intravenous infusion bag containing sodium chloride 9 mg/mL (0.9%) or dextrose 50 mg/mL (5%) for infusion. Mix the diluted solution by gentle inversion. The final concentration of the diluted solution should be between 0.5 mg/mL and 20 mg/mL. Do not freeze or shake the solution. Discard any unused portion left in the vial.
- 4. Once prepared, administer the diluted solution immediately. If the diluted solution is not administered immediately, it may be stored temporarily either:
 - under refrigeration at 2°C to 8°C for no more than 24 hours from the time of infusion preparation to the end of the infusion.
 - at room temperature up to 25°C for no more than 6 hours from the time of infusion preparation to the end of the infusion.



Please visit evkeeza.ca for more information

or visit ultracaresupport.ca for our patient support program.



Administration¹

- 1. If refrigerated, allow the solution to come to room temperature (up to 25°C) prior to administration.
- 2. Administer FVKFF7A over 60 minutes by intravenous (IV) infusion only through an intravenous line containing a sterile, in-line or add-on 0.2-micron to 5-micron filter
- 3. Do not administer EVKEEZA as an IV push or bolus. Do not mix other medicinal products with EVKEEZA or administer concomitantly via the same infusion line.
- 4. The rate of infusion may be slowed, interrupted or discontinued if the patient develops any signs of adverse reactions, including infusion-associated symptoms.
- 5. Dispose of any unused medicinal product or waste material in accordance with local requirements.

EVKEEZA should only be administered by a healthcare professional.

Non-medicinal ingredients:

- L-arginine hydrochloride
- L-histidine
- L-histidine monohydrochloride monohydrate
- L-proline
- Polysorbate 80
- Water for injection

REFERENCE:

1. EVKEEZA Product Monograph, Ultragenyx Pharmaceutical, Inc. 2025.

